Astellas banks on existing data in surprise US re-filing of once-daily tacrolimus
This article was originally published in Scrip
After mulling on the quiet for several years whether to go ahead or not, Astellas has finally filed a US NDA for the once-daily capsule formulation of its immunosuppressant tacrolimus.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.